Lung and respiratory diseases
24 public biotech companies we cover are developing treatments for pulmonary hypertension, pulmonary fibrosis, asthma, COPD and cystic fibrosis. 7 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- Aclaris Therapeutics (ACRS)Thesis Intact
Asthma
- Akebia Therapeutics (AKBA)Thesis Intact
Acute respiratory distress syndrome
- Arcus Biosciences (RCUS)Thesis Intact
Asthma
- Arrowhead Pharmaceuticals (ARWR)Thesis Intact
Idiopathic pulmonary fibrosis, Inflammatory pulmonary disease
- Bolt Biotherapeutics (BOLT)Thesis Broken
Asthma
- Contineum Therapeutics (CTNM)Thesis Challenged
Idiopathic pulmonary fibrosis
- Corvus Pharmaceuticals (CRVS)Thesis Intact
Asthma
- Equillium (EQ)Thesis Intact
Inflammatory lung disease
- Gossamer Bio (GOSS)Thesis Challenged
Pulmonary arterial hypertension, Pulmonary hypertension associated with interstitial lung disease
- iBio (IBIO)Thesis Intact
Pulmonary hypertension
- InflaRx (IFRX)Thesis Intact
Acute respiratory distress syndrome
- Inhibikase Therapeutics (IKT)Thesis Intact
Pulmonary arterial hypertension
- IRulya Therapeutics (IRLA)Thesis Intact
Post-lung transplant, Bronchiolitis obliterans syndrome, Sarcoidosis-associated pulmonary hypertension, Pulmonary hypertension associated with interstitial lung disease
- Liquidia (LQDA)Thesis Intact
PH-ILD, Pulmonary arterial hypertension, Pulmonary hypertension associated with interstitial lung disease
- Omeros (OMER)Thesis Challenged
Hyperinflammatory ARDS
- Precigen (PGEN)Thesis Intact
Recurrent respiratory papillomatosis
- Prime Medicine (PRME)Thesis Challenged
Cystic Fibrosis
- Rein Therapeutics (RNTX)Thesis Intact
Cystic fibrosis, Loculated pleural effusion, Idiopathic pulmonary fibrosis
- Roivant Sciences (ROIV)Thesis Intact
Pulmonary hypertension, Pulmonary hypertension associated with interstitial lung disease
- Sionna Therapeutics (SION)Thesis Challenged
Cystic fibrosis
- Structure Therapeutics (GPCR)Thesis Intact
Idiopathic pulmonary fibrosis
- Tectonic Therapeutic (TECX)Thesis Intact
Pulmonary hypertension, Interstitial lung disease, Pulmonary hypertension associated with interstitial lung disease
- Tenax Therapeutics (TENX)Thesis Broken
Pulmonary hypertension, Pulmonary arterial hypertension
- Tiziana Life Sciences (TLSA)Thesis Challenged
Interstitial lung disease
Drug pages
Upcoming catalysts
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in Q4 2026
- Q4 2026ATI-052 · Phase 2b start · Asthma
- Q4 2026LTI-03 · Phase 2 interim results (RENEW) · Idiopathic pulmonary fibrosis
Expected in H2 2026
- H2 2026Soquelitinib · Phase 2 start · Asthma
Expected by end of 2026
- year-end 2026Narsoplimab · Trial start · Hyperinflammatory ARDS
Expected in Q1 2027
- Q1 2027LAM-001 · Phase 2 results · Bronchiolitis obliterans syndrome · post-lung transplant
- Q1 2027SION-451 / SION-2222 · Phase 2a start (AscenSION CF) · Cystic fibrosis · F508del homozygous
- early Q1 2027TX45 · Phase 2 topline results (APEX) · Pulmonary hypertension · heart failure with preserved ejection fraction